Measles Hearings Offer Counterpoint To Pricing Spotlight: Vaccines Touted As Cost-Effective Solution To Outbreaks
Congressional hearings on the recent outbreaks of measles and other vaccine-preventable diseases offered a positive theme for the industry during the ongoing drug pricing debate.
You may also be interested in...
What do CBD advocates and anti-vaxxers have in common? A fundamental mistrust in the public health establishment. That should be a call to action for public health agencies and the biopharma industry.
Vaccination policies could result in arguments over states' rights instead of public health concerns, outgoing US FDA commissioner warns.
Industry's top leaders weren't exactly eager to testify on Capitol Hill. Now they might be wondering why they waited so long. Seven pharma leaders avoided missteps during a Senate Finance Committee hearing on drug pricing Feb. 26.